GelMEDIX

About GelMEDIX

GelMEDIX is a regenerative medicine company focused on combating vision loss through a biomaterials platform. Its lead program targets Geographic Atrophy, a leading cause of blindness in older adults, leveraging iPSC-derived retinal pigment epithelial (RPE) cell therapy supported by a hydrogel scaffold. The approach aims to regenerate retinal tissue and preserve vision by addressing defects in the retina while avoiding risks seen in prior therapies. The company is based in Cambridge, Massachusetts, and is advancing preclinical work toward restoring sight.